FDA will be key in pharma's adoption of personalized medicine

09/26/2013 | Forbes

The FDA's attitude will be crucial to the willingness of drugmakers to adopt personalized medicine and its wider application, writes Henry I. Miller, the founding director of the FDA Office of Biotechnology. Huge development costs could be imposed by the regulatory demand for extensive clinical trials to prove new drugs' safety as well as the need to develop biomarkers to go with these drugs, he writes. Furthermore, the diminished revenue potential may in the end become unsustainable for drugmakers, he writes.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA